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The fibrillar protein collagen type II (CII) is essentially confined to hyaline 
cartilage in diarthrodal joints. Antibodies against CII (anti-CII) were previously 
described in 3-27% of rheumatoid arthritis (RA) patients, and Kim et al. 
described anti-CII to be associated with elevated levels of CRP and ESR in a 
heterogeneous group of RA patients with 2-432 months of disease duration. [1] 
Contrary to anti-citrullinated protein antibodies, anti-CII are not detected before 
RA onset. [2] We have shown that anti-CII levels are highest at the time of RA 
diagnosis and thereafter decline, and that elevated anti-CII levels at diagnosis 
associate with elevated CRP, ESR, swollen joint count, disease activity score and 
radiological destruction at the time of diagnosis but not later, thus representing 
an acute onset RA phenotype. [3-5] It is plausible that production of pro-
inflammatory cytokines by macrophages is stimulated by anti-CII-containing 
immune complexes (IC) in RA joints, as anti-CII producing B cells are detectable 
in synovial fluid but not in the circulation. [6, 7] Analogously, in rodents, collagen 
antibody-induced arthritis (CAIA) develops soon after injection of a defined 
blend of anti-CII antibodies. [8] Polymorphonuclear granulocytes (PMN) are 
central in CAIA pathogenesis, and we have recently shown that PMN induce 
chemokine production after stimulation with IC containing anti-CII from RA 
patients. [9]  
In patients with very early synovitis with ≤3 months duration, anti-CII are not 
more common in patients developing RA than in patients developing other 
diagnoses during the following year. [10] Post-publication subgroup analysis 
showed that 3/11 (27%) of reactive arthritis and 2/7 (29%) of gouty arthritis 
patients had elevated anti-CII levels at the early synovitis stage (unpublished). 
As both reactive arthritis and gouty arthritis often have an acute arthritis onset, 
we hypothesized that high levels of anti-CII might not only be a marker of acute 
onset RA, but a marker of acute onset arthritis in general. 
 
To investigate the hypothesis that high anti-CII levels might be a general marker 
of acute onset arthritides we collected first visit sera from 26 patients with gouty 
arthritis, 3 patients with pseudogout, 44 patients with reactive arthritis, and 33 
patients with remitting seronegative symmetrical synovitis with pitting edema 
(RS3PE), diagnoses that often start with acute onset arthritis. Patient 
characteristics are described in table 1. Antibodies against native human CII 
were measured with ELISA, and levels above the 95th percentile among controls 
were regarded as positive in agreement with our previous studies. [4-6] Serially 
followed internal laboratory controls showed that the analysis performance 
remained unaltered. [3, 4]   
Eight of the 106 (7.5%) first visit non-RA patients were anti-CII positive, very 
similar to our previously published data on early RA (6.6-8.8%). [3, 4] There was 
no significant difference between any diagnostic groups (table 1). Only 
moderately elevated anti-CII levels were found; no non-RA patients exhibited 
very high anti-CII levels comparable to the high outlier group that we have 
described in early RA patients (figure 1). [4, 5] 
We conclude that although high anti-CII levels are associated with acute onset in 
RA, this cannot be generalized to most patients with other acute onset 
arthritides. 
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Table 1. Patient characteristics for the investigated patients. Not all patients had 









Number 26 3 44 33 106 274 
Female; 
number (%) 








































11 (1-12) 2 (1-4) 3 (1-6) 2 (1-6) 9 (5-13) 
TJC (66 joint 
count); 
median (IQR) 
4 (1-6) 13 (1-17) 3 (2-5) 5 (2-
10.5) 





















0/3 (0) 1/12 
(8.3) 

















* samples yielding > 29 AU/ml of anti-CII and showing lower OD in bovine serum 
albumin blocked control wells without CII than in anti-CII coated and 
subsequently blocked wells. $ patients presenting with an inflammatory arthritis 
of at least one joint in which calcium pyrophosphate crystals were identified in 
synovial fluid microscopy and in whom no alternative diagnosis was made. 
Figure 1. Levels of antibodies against native human collagen type II. The dotted 
horizontal line represent the cutoff based on the 95th percentile among healthy 
controls (29 arbitrary units/ml). Values above the cutoff are divided into true 
positive samples (triangles) and samples with non-specific binding (stars) 
reacting with higher OD levels in control wells coated only with bovine serum 
albumin. Only true positive values are reported as positive in table 1. Solid 
horizontal bars represent median values in each group. ReA= reactive arthritis, 
RS3PE= remitting seronegative symmetrical synovitis with pitting edema, 
RA=rheumatoid arthritis. Data on the 274 RA patients were published 
previously. [4, 5] 
 
 
